British employees of pharma giant GlaxoSmithKline (GSK) have voted to strike against the company’s recent pay raise. The employees are backed by British labor union Unite.
RMAT designation means a faster, more streamlined approval process and frequent communication with FDA representatives. The FDA recently granted RMAT Designations to both Direct Bio and AlloVir.
The major money winners this week included a DNA editing platform, a machine-learning platform that creates digital patient “twins” and wearable temperature-monitoring patches.
Axsome Therapeutics received good news regarding its NDA for AXS-05, a treatment for depression, and Aytu BioScience received Fast Track designation for its VEDS treatment.
Global biopharmaceutical companies are pooling their respective resources against difficult-to-treat tumors, CNS diseases and idiopathic pulmonary fibrosis.
Be Biopharma closed a massive $130M financing to further its proprietary autologous and allogeneic BeCM platform and discover therapies for cancer, rare diseases and more.
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
Curis, a biotech company that develops treatments for cancer, has announced that the FDA has placed a partial clinical hold on its TakeAim lymphoma study.
mRNA therapies are the future of treatments for many different conditions. Now, other types of RNA therapy are getting attention too, and it’s sparking exciting new developments.
Researchers at the Babraham Research Institute have developed a new technique for rejuvenating skin cells, which can rewind the biological clock of patients by about 30 years.
Six months after acquiring Kadmon Holdings, pharma giant Sanofi is closing Kadmon’s New York facility. As part of the paring down, Sanofi is also laying off 25 employees at the location.
